QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 genprex-reports-clinical-study-updates-from-acclaim-1-and-acclaim-3-phase-12-clinical-trials-in-lung-cancer

Demonstrates Prolonged Progression Free Survival of Two Patients in Acclaim-1 and Partial Remission from Maintenance Therapy in...

 genprex-granted-patent-in-singapore-for-reqorsa-gene-therapy-in-combination-with-pd-1-antibodies-through-2037

Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors

 genprex-issues-letter-and-provides-2024-update-reached-multiple-clinical-development-milestones-in-2024-patient-treatment-continues-in-three-lung-cancer-clinical-trials

https://www.genprex.com/downloads/2024-genprex-stockholder-letter.pdf 

 hc-wainwright--co-reiterates-buy-on-genprex-maintains-10-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.

 hc-wainwright--co-reiterates-buy-on-genprex-maintains-10-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.

 genprex-administers-first-dose-in-acclaim-3-clinical-study-of-reqorsa-immunogene-therapy-combined-with-tecentriq-to-treat-small-cell-lung-cancer

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on deve...

 genprex-earlier-reported-preclinical-data-for-reqorsa-immunogene-therapy-and-nprl2-gene-therapy-for-lung-cancer

Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer T...

 hc-wainwright--co-reiterates-buy-on-genprex-maintains-10-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.

 genprex-expands-clinical-trial-sites-for-acclaim-3-clinical-study-of-reqorsa-therapy-in-combination-with-tecentriq-for-small-cell-lung-cancer

 Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices       ...

 hc-wainwright--co-reiterates-buy-on-genprex-maintains-10-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.

 genprex-publishes-preclinical-data-with-nprl2-gene-therapy-using-oncoprex-delivery-system

NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanize...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION